A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma
Jesús G. Berdeja(Tennessee Oncology), Sagar Lonial(Emory University), Shambavi Richard(Medical Oncology Hematology Consultants), Paul G. Richardson(Harvard University), Michelle Mahler(C4 Therapeutics (United States)), Sikander Ailawadhi(Jacksonville College), Manisha Bhutani(Carolinas Healthcare System), Andrew J. Yee(Harvard University), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Eli Muchtar(Mayo Clinic), Oliver Schönborn‐Kellenberger(C4 Therapeutics (United States)), Sanela Bilic, Michael R. Palmer(C4 Therapeutics (United States)), Jeffrey Matous(Colorado Blood Cancer Institute), Cathleen Gorman(C4 Therapeutics (United States)), Thomas G. Martin(University of Colorado Boulder), Adam Crystal(C4 Therapeutics (United States))
Cited by 22
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k